AnesthesiaROBOTNOLNCT04566536
NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery
An observational study of Anesthesia and Pain Management, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Anesthesia quality and safety have improved over the past decades, thanks to improved monitoring devices. No nociception monitoring is currently part of the standard of care. Usually, hemodynamic parameters are used to evaluate nociception (heart rate, HR, and mean arterial pressure, MAP), but none of them are… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anesthesia, Pain Management
- How many people
- 83 participants
- Where
- 1 siteFrance
- Study dates
- 7 Oct 2020to 22 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients undergoing robotic surgery in Bichat Hospital, APHP, Paris, France
Who may be able to join
- Age ≥ 18 years old
- Scheduled for a robotic surgery in the center of investigation (all specialties except cardiac and ENT: gynaecologic, thoracic, urologic and abdominal)
- Non-opposition to the study participation
Who cannot join
- Age < 18 years old
- Rapid sequence anaesthesia required
- Pregnancy and breast feeding
- Chronic medication by any pain killer (opioids or not)
- ENT and cardiac robotic surgery
- Neuromuscular disease
Show all 11Show fewer
- NoL Index contre-indications, such as cardiac arrythmia, supra-clavicular arterial stenosis, severe hypovolemia, severe hypothermia
- Chronic alcoholism, toxicomania
- Severe obesity (IMC > 35)
- Legal protection
- Opposition to the study participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery Under Propofol-remifentanil Anaesthesia
Anesthesia quality and safety have improved over the past decades, thanks to improved monitoring devices. No nociception monitoring is currently part of the standard of care. Usually, hemodynamic parameters are used to evaluate nociception (heart rate, HR, and mean arterial pressure, MAP), but none of them are specific. However, nociception evaluation is critical. Indeed, where excess of nociception can lead to arterial hypotension and respiratory depression, insufficient nociception can lead to acute postoperative pain, which is followed by persistent chronic pain in 10-50% of patients. Different monitoring devices have been developed but none of them are still used in current practice. Recently developed, the nociception level (NoL) index (MEDASENSE BIOMETRICS Ltd®, Ramat Gan, Israel) is an index of nociception, based on a nonlinear algorithm combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be mini-invasive with less hemorrhage complications, with better success based on the technical advantages of the robot allowing better access during anatomical challenges procedures. Robotic surgery has been suggested to decrease pain during surgery and post-operatively, because of the decreases abdominal wall constraints induced by the robotic arms compared to the surgeon arms.
Read more
This observational prospective non-interventional monocentric study intend to evaluate the performance of the NoL index to discriminate protocol-defined nociceptive from non nociceptive stimuli during robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the study during the anesthesia consultation. During the procedure, the anesthesia procedure will be the same for all patients, as part of the usual care in our department. The NoL monitor will be added for the purpose of this study, but the results will be hidden from all physicians. All settings will be left the physician in charge. At the end of the surgical procedure, before transfer to the recovery room, data for the monitor will be extracted on a dedicated universal serial bus (USB) key. Files will be safely stored under RedCap before analysis.
Read the detailed description
Anesthesia quality and safety have improved over the past decades, thanks to improved monitoring devices. Excess of anesthetics could lead to arterial hypotension which has been shown to be associated with increased cardiovascular events. On the other hand, insufficient anesthetics could lead to awareness and memorization during general anesthesia (GA). Whereas almost all drugs currently used in the operating room (OR), have a validated monitoring tool, no nociception monitoring is currently part of the standard of care. Usually, hemodynamic parameters are used to evaluate nociception (heart rate (HR), and mean arterial pressure (MAP)), but none of them are specific and several factors in the OR influence these parameters. There is growing interest in the literature for nociception monitoring. Indeed, where excess of nociception can lead to arterial hypotension and respiratory depression, insufficient nociception can lead to acute postoperative pain, which is followed by persistent chronic pain in 10-50% of patients. Opioids per se can also induce nausea and vomiting, hyperalgesia for remifentanil.
Different monitoring devices, like the surgical pleth index, pupillometry or the "Analgesia Nociception Index", have been developed, based on several variables and algorithms, but none of them are still used in current practice. One of the major reason is that although they might had some effects on clinical parameters or drugs consumption, none of them had any influence on patient outcome. Recently developed, the nociception level (NoL) index (MEDASENSE BIOMETRICS Ltd®, Ramat Gan, Israel) is an index of nociception, based on a nonlinear algorithm combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives. One of the first study to report the ability of the NoL index to discriminate noxious from non-noxious stimuli with high sensitivity and specificity was performed in 2016. In that randomized trial (continuous infusion of remifentanil target 2 versus 4 ng/ml) enrolling 58 patients undergoing a large range of surgery, the NoL index was superior than the hemodynamic parameters alone to characterize nociception. In a study enrolling 72 patients randomized within 6 remifentanil concentration targets undergoing several surgical procedures by the same authors, the NoL index was not affected by remifentanil doses, whereas it had an dose-dependent hemodynamic effect on HR and MAP.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be mini-invasive with less hemorrhage complications, with better success based on the technical advantages of the robot allowing better access during anatomical challenges procedures. Debates recently arise based on the procedures cost and the little (or lack) of evidence of mini-invasive procedures in patients with cancers. Robotic surgery has been suggested to decrease pain during surgery and post-operatively, in gynecologic, thoracic, and general procedures although results are controversial, because of the decreases abdominal wall constraints induced by the robotic arms compared to the surgeon arms. To our knowledge, none of these studies evaluated pain based on a nociception monitoring device.
This observational prospective non-interventional monocentric study intend to evaluate the performance of the NoL index to discriminate nociceptive from non nociceptive stimuli during robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the study during the anesthesia consultation. During the procedure, the anesthesia procedure will be the same for all patients, as part of the usual care in our department. Patients will be closely monitored by electrocardiogram, intermittent blood pressure by arm cuff, continuous pulse oximetry by finger probe, neuromuscular monitoring by train-of-four (TOF)-Cuff, bispectral index (BIS) monitoring using the BIS forehead 4-sensor. The NoL monitor will be added for the purpose of this study, but the results will be hidden. The probe will be placed on the hand contralateral to the blood pressure arm cuff. Anesthesia will be delivered by target-controlled infusion of remifentanil and propofol by two separate infusion pumps. Once consciousness will be lost and a TOF calibration done, neuromuscular blockade will be performed by rocuronium 0.6 mg/kg. All settings will be left the physician appreciation. Different stimuli (nociceptive and non-nociceptive) are defined according to protocol (such as intubation, incision, surgical haemostasia, urinary track catheter…) and their time of arrival will be collected in a Case Report Form. At the end of the surgical procedure, before transfer to the recovery room, data for the monitor will be extracted on a dedicated USB key. Files will be safely stored under RedCap before analysis.
- Conditions
- Anesthesia, Pain Management
- Keywords
- NoL, Nociception, Robotic surgery
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Surgery | Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
NoL index validation
Area under the curve with the 95% confidence interval, based on the NoL absolute value after nociceptive and non-nociceptive stimuli.
Measured: 7 hours
Secondary outcomes (6)
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the heart rate after nociceptive and non-nociceptive stimuli.
Sensitivity, specificity and area under the curve
Measured: 7 hours
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the mean arterial pressure
Sensitivity, specificity and area under the curve of the mean arterial pressure after nociceptive and non-nociceptive stimuli.
Measured: 7 hours
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the BIS index
Sensitivity, specificity and area under the curve of the BIS index after nociceptive and non-nociceptive stimuli.
Measured: 7 hours
Correlation between the NoL index and the mean arterial pressure during nociceptive stimuli
Spearman correlation test within the NoL index variations and the mean arterial pressure variations after each stimuli
Measured: 7 hours
Correlation between the NoL index and the heart rate during nociceptive stimuli
Spearman correlation test within the NoL index variations and the heart rate variations after each stimuli
Measured: 7 hours
Delay of the NoL index to detect a nociceptive stimuli
Delay between a NoL index above 25 and the nociceptive stimuli
Measured: 7 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2020
- Study start7 Oct 2020
- Primary completion22 Apr 2022
- Study completion22 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnesthesiaStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 83 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Aurélie GOUEL-CHERON, MD, PhD, Principal investigator, Hôpital Bichat-Claude Bernard, AP-HP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04566536
- Sponsor's protocol ID
- APHP191091
- Other IDs
- 2019-A02744-53
- Acronym
- ROBOTNOL
- Status last verified
- Apr 2023
- First submitted
- 14 Sep 2020
- Last updated
- 10 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NoL Monitor Performances of Nociceptive and Non-nociceptive Stimuli Discrimination During Robotic Surgery Under Propofol-remifentanil Anaesthesia
- ClinicalTrials.gov ID
- NCT04566536
- Acronym / sponsor ID
- ROBOTNOL / APHP191091
- Conditions
- Anesthesia, Pain Management
- Keywords
- NoL, Nociception, Robotic surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 83 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 7 Oct 2020 (actual)
- Primary completion
- 22 Apr 2022 (actual)
- Study completion
- 22 Apr 2022 (actual)
- First posted
- 28 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Anesthesia quality and safety have improved over the past decades, thanks to improved monitoring devices. No nociception monitoring is currently part of the standard of care. Usually, hemodynamic parameters are used to evaluate nociception (heart rate, HR, and mean arterial pressure, MAP), but none of them are specific. However, nociception evaluation is critical. Indeed, where excess of nociception can lead to arterial hypotension and respiratory depression, insufficient nociception can lead to acute postoperative pain, which is followed by persistent chronic pain in 10-50% of patients. Different monitoring devices have been developed but none of them are still used in current practice. Recently developed, the nociception level (NoL) index (MEDASENSE BIOMETRICS Ltd®, Ramat Gan, Israel) is an index of nociception, based on a nonlinear algorithm combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be mini-invasive with less hemorrhage complications, with better success based on the technical advantages of the robot allowing better access during anatomical challenges procedures. Robotic surgery has been suggested to decrease pain during surgery and post-operatively, because of the decreases abdominal wall constraints induced by the robotic arms compared to the surgeon arms.
This observational prospective non-interventional monocentric study intend to evaluate the performance of the NoL index to discriminate protocol-defined nociceptive from non nociceptive stimuli during robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the study during the anesthesia consultation. During the procedure, the anesthesia procedure will be the same for all patients, as part of the usual care in our department. The NoL monitor will be added for the purpose of this study, but the results will be hidden from all physicians. All settings will be left the physician in charge. At the end of the surgical procedure, before transfer to the recovery room, data for the monitor will be extracted on a dedicated universal serial bus (USB) key. Files will be safely stored under RedCap before analysis.
Detailed description
Anesthesia quality and safety have improved over the past decades, thanks to improved monitoring devices. Excess of anesthetics could lead to arterial hypotension which has been shown to be associated with increased cardiovascular events. On the other hand, insufficient anesthetics could lead to awareness and memorization during general anesthesia (GA). Whereas almost all drugs currently used in the operating room (OR), have a validated monitoring tool, no nociception monitoring is currently part of the standard of care. Usually, hemodynamic parameters are used to evaluate nociception (heart rate (HR), and mean arterial pressure (MAP)), but none of them are specific and several factors in the OR influence these parameters. There is growing interest in the literature for nociception monitoring. Indeed, where excess of nociception can lead to arterial hypotension and respiratory depression, insufficient nociception can lead to acute postoperative pain, which is followed by persistent chronic pain in 10-50% of patients. Opioids per se can also induce nausea and vomiting, hyperalgesia for remifentanil.
Different monitoring devices, like the surgical pleth index, pupillometry or the "Analgesia Nociception Index", have been developed, based on several variables and algorithms, but none of them are still used in current practice. One of the major reason is that although they might had some effects on clinical parameters or drugs consumption, none of them had any influence on patient outcome. Recently developed, the nociception level (NoL) index (MEDASENSE BIOMETRICS Ltd®, Ramat Gan, Israel) is an index of nociception, based on a nonlinear algorithm combination of heart rate, heart rate variability, photoplethysmograph wave amplitude, skin conductance, skin conductance fluctuations, and their time derivatives. One of the first study to report the ability of the NoL index to discriminate noxious from non-noxious stimuli with high sensitivity and specificity was performed in 2016. In that randomized trial (continuous infusion of remifentanil target 2 versus 4 ng/ml) enrolling 58 patients undergoing a large range of surgery, the NoL index was superior than the hemodynamic parameters alone to characterize nociception. In a study enrolling 72 patients randomized within 6 remifentanil concentration targets undergoing several surgical procedures by the same authors, the NoL index was not affected by remifentanil doses, whereas it had an dose-dependent hemodynamic effect on HR and MAP.
Robotic surgeries have started to spread over the world 20 years ago, claiming to be mini-invasive with less hemorrhage complications, with better success based on the technical advantages of the robot allowing better access during anatomical challenges procedures. Debates recently arise based on the procedures cost and the little (or lack) of evidence of mini-invasive procedures in patients with cancers. Robotic surgery has been suggested to decrease pain during surgery and post-operatively, in gynecologic, thoracic, and general procedures although results are controversial, because of the decreases abdominal wall constraints induced by the robotic arms compared to the surgeon arms. To our knowledge, none of these studies evaluated pain based on a nociception monitoring device.
This observational prospective non-interventional monocentric study intend to evaluate the performance of the NoL index to discriminate nociceptive from non nociceptive stimuli during robotic surgery.
All patients, scheduled for a robotic surgery procedure, will be orally informed about the study during the anesthesia consultation. During the procedure, the anesthesia procedure will be the same for all patients, as part of the usual care in our department. Patients will be closely monitored by electrocardiogram, intermittent blood pressure by arm cuff, continuous pulse oximetry by finger probe, neuromuscular monitoring by train-of-four (TOF)-Cuff, bispectral index (BIS) monitoring using the BIS forehead 4-sensor. The NoL monitor will be added for the purpose of this study, but the results will be hidden. The probe will be placed on the hand contralateral to the blood pressure arm cuff. Anesthesia will be delivered by target-controlled infusion of remifentanil and propofol by two separate infusion pumps. Once consciousness will be lost and a TOF calibration done, neuromuscular blockade will be performed by rocuronium 0.6 mg/kg. All settings will be left the physician appreciation. Different stimuli (nociceptive and non-nociceptive) are defined according to protocol (such as intubation, incision, surgical haemostasia, urinary track catheter…) and their time of arrival will be collected in a Case Report Form. At the end of the surgical procedure, before transfer to the recovery room, data for the monitor will be extracted on a dedicated USB key. Files will be safely stored under RedCap before analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Surgery | – | –Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing robotic surgery in Bichat Hospital, APHP, Paris, France
Key inclusion criteria (3 listed)
- Age ≥ 18 years old
- Scheduled for a robotic surgery in the center of investigation (all specialties except cardiac and ENT: gynaecologic, thoracic, urologic and abdominal)
- Non-opposition to the study participation
Key exclusion criteria (11 listed)
- Age < 18 years old
- Rapid sequence anaesthesia required
- Pregnancy and breast feeding
- Chronic medication by any pain killer (opioids or not)
- ENT and cardiac robotic surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
NoL index validation
Time frame: 7 hours
Area under the curve with the 95% confidence interval, based on the NoL absolute value after nociceptive and non-nociceptive stimuli.
6 secondary outcomes
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the heart rate after nociceptive and non-nociceptive stimuli.
Time frame: 7 hours
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the mean arterial pressure
Time frame: 7 hours
Discriminative diagnosis performance (nociceptive from non-nociceptive stimuli) of the BIS index
Time frame: 7 hours
Correlation between the NoL index and the mean arterial pressure during nociceptive stimuli
Time frame: 7 hours
Correlation between the NoL index and the heart rate during nociceptive stimuli
Time frame: 7 hours
Delay of the NoL index to detect a nociceptive stimuli
Time frame: 7 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Anesthesia
Not yet recruitingObservational study
"Comparison of Oxygen Reserve Index (ORI), End-Tidal Oxygen, and Time-Based Preoxygenation Targets With Arterial Blood Gas During Preoxygenation
Preoxygenation Adequacy Assessed by Oxygen Reserve Index, End-tidal Oxygen and Arterial Blood Gas
RecruitingObservational study
Comparison of Hemodynamic Responses During Anesthesia Induction Using Eleveld and Schnider
Spinal (Fusion) Surgery, Total Intravenous Anesthesia
Not yet recruiting
A Randomized Controlled SaCo-VLM Trial
General Anaesthesia Using Supraglotic Airway
Not yet recruiting
Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography
Deep Sedation, Endoscopic Retrograde Cholangiopancreatography
RecruitingPhase 4
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aurélie GOUEL-CHERON, MD, PhD principal investigator
Hôpital Bichat-Claude Bernard, AP-HP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anesthesia and Pain Management, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NoL index validation (time frame: 7 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2023.